RxDoctor Payments Data

Muhammad Mohyuddin, MD

Geriatric Medicine · Columbus, GANPI 1598965352

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Abiomed at 38.6% of the total. 2025 is the largest year on record at $180, 5.2 times the $35 reported in 2019.

$388in general payments, 2019–2025

Across 11 payments — averaging $35.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$150
  • Abbott$116
  • Novartis$35
  • Bayer$30
  • Esperion Therapeutics, Inc.$21
  • Alnylam Pharmaceuticals Inc.$21
  • plus $16 from 2 others

What the payments were for

  • Food & beverage$388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$388 in reported general payments places this provider in the 65th percentile of 75 geriatric medicine providers in Georgia.

See all geriatric medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$127,737
Medicare patients
239
Services billed
2,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban354$124,216
XareltoRivaroxaban97$38,061
OzempicSemaglutide23$28,412
FarxigaDapagliflozin Propanediol26$26,836
EntrestoSacubitril/Valsartan73$23,019
RybelsusSemaglutide18$17,468
CreonLipase/Protease/Amylase49$15,202
JanuviaSitagliptin Phosphate20$8,812
Potassium Chloride378$7,595
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,475
Atorvastatin Calcium579$5,955
BrilintaTicagrelor13$5,709
Colesevelam Hcl63$5,589
JardianceEmpagliflozin13$5,066
Levothyroxine Sodium530$4,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$14$45,87941 claims
NovartisEntresto$35$23,01973 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 75 geriatric medicine providers in Georgia.

Other geriatric medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →